1. [P4–567]: A PHASE 1 SAFETY TRIAL OF THE Aβ OLIGOMER RECEPTOR ANTAGONIST CT1812. (1st July 2017) Authors: Catalano, Susan; Grundman, Michael; Schneider, Lon S.; DeKosky, Steven; Morgan, Roger; Guttendorf, Robert; Higgin, Michelle; Pribyl, Julie; Mozzoni, Kelsie; Izzo, Nicholas J.; Safferstein, Hank Journal: Alzheimer's & dementia Issue: Volume 13:Supplement 7S(2017)Part 32 Page Start: P1570 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A phase 1 clinical trial of the sigma‐2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease. Issue 1 (18th December 2018) Authors: Grundman, Michael; Morgan, Roger; Lickliter, Jason D.; Schneider, Lon S.; DeKosky, Steven; Izzo, Nicholas J.; Guttendorf, Robert; Higgin, Michelle; Pribyl, Julie; Mozzoni, Kelsie; Safferstein, Hank; Catalano, Susan M. Journal: Alzheimer's & dementia Issue: Volume 5:Issue 1(2019) Page Start: 20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P4‐381: A Two‐Part, Double‐Blind, Placebo‐Controlled, Phase 1 Study of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of CT1812 in Healthy Volunteers. (1st July 2016) Authors: Catalano, Susan; Grundman, Michael; Schneider, Lon S.; DeKosky, Steven; Morgan, Roger; Higgin, Michelle; Pribyl, Julie; Mozzoni, Kelsie; Izzo, Nicholas J.; Safferstein, Hank; Lickliter, Jason Journal: Alzheimer's & dementia Issue: Volume 12:Supplement 7S(2014)Part 24 Page Start: P1183 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗